Fidelis Capital Partners LLC Has $282,000 Holdings in CVS Health Co. (NYSE:CVS)

Fidelis Capital Partners LLC trimmed its stake in CVS Health Co. (NYSE:CVS) by 13.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 6,276 shares of the pharmacy operator’s stock after selling 1,010 shares during the quarter. Fidelis Capital Partners LLC’s holdings in CVS Health were worth $282,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of CVS. Assetmark Inc. increased its position in shares of CVS Health by 9.7% during the 3rd quarter. Assetmark Inc. now owns 410,001 shares of the pharmacy operator’s stock worth $25,781,000 after purchasing an additional 36,132 shares in the last quarter. TD Private Client Wealth LLC grew its stake in CVS Health by 28.7% during the third quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator’s stock worth $2,951,000 after buying an additional 10,465 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of CVS Health by 4.8% during the third quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator’s stock worth $90,200,000 after buying an additional 66,244 shares in the last quarter. Sompo Asset Management Co. Ltd. boosted its holdings in shares of CVS Health by 8.4% in the 3rd quarter. Sompo Asset Management Co. Ltd. now owns 134,523 shares of the pharmacy operator’s stock worth $8,459,000 after acquiring an additional 10,453 shares in the last quarter. Finally, Hall Laurie J Trustee grew its position in CVS Health by 25,484.4% during the 4th quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator’s stock worth $517,000 after acquiring an additional 11,468 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Michael F. Mahoney bought 30,000 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the acquisition, the director now owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 0.24% of the stock is currently owned by company insiders.

CVS Health Stock Performance

Shares of NYSE:CVS opened at $64.26 on Wednesday. The company has a market capitalization of $81.01 billion, a price-to-earnings ratio of 17.56, a P/E/G ratio of 0.98 and a beta of 0.61. The firm’s 50 day simple moving average is $55.14 and its 200 day simple moving average is $56.58. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $80.75.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. As a group, sell-side analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.14%. The ex-dividend date of this dividend was Thursday, January 23rd. CVS Health’s dividend payout ratio is currently 72.68%.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of recent analyst reports. Wolfe Research boosted their price objective on CVS Health from 67.00 to 70.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. UBS Group reduced their price target on shares of CVS Health from $62.00 to $59.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 11th. Deutsche Bank Aktiengesellschaft upgraded shares of CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a research report on Tuesday, December 3rd. Leerink Partnrs raised shares of CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 12th. Finally, Leerink Partners upgraded shares of CVS Health from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $55.00 to $75.00 in a research report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $69.83.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.